Suanfarma Suanfarma

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu
    [{"orgOrder":0,"company":"Aksigen Hospital Care","sponsor":"Sun Pharmaceutical Industries Limited","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Sun Pharma Acquires Disperzyme\u00ae and Phlogam\u00ae Brands to Strengthen Its Anti-Inflammatory Portfolio","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"INDIA","productType":"Small molecule","productStatus":"Approved","date":"January 2023","url1":"","url2":"","graph1":"Neurology","graph2":"Approved"}]

    Find Clinical Drug Pipeline Developments & Deals by Aksigen Hospital Care

    Menu

    Aksigen Hospital Care

    EVENTS

    • Webinars & Exhibitions

    PRESENTATION(s)

    VIDEO(s)

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Loading...

    All Data

    Previous
    Next
    Filters Filter
    ×
    FILTER:
    filter Company
      filter Sponsor
        filter Country
          filter Therapeutic Area
            filter Study Phase

              Active Filter(s):

              refreshFilters
              refreshReset Filter
              refresh Reset Filter
              price-trend All Developments

              Companies By Therapeutic Area

              Development Status

              Aksigen Hospital Care

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag India
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Sun Pharma Acquires Disperzyme® and Phlogam® Brands to Strengthen Its Anti-Inflammatory Portfolio

              Details:

              Through the acquisition, Sun Pharma strengthen its anti-inflammatory portfolio by adding Disperzyme (bromelain), Disperzyme-CD and Phlogam from Aksigen Hospital Care.

              Lead Product(s): Bromelain,Trypsin,Rutin

              Therapeutic Area: Neurology Product Name: Disperzyme

              Highest Development Status: Approved Product Type: Small molecule

              Partner/Sponsor/Collaborator: Sun Pharmaceutical Industries Limited

              Deal Size: Undisclosed Upfront Cash: Undisclosed

              Deal Type: Acquisition January 30, 2023

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity
              Inke S.A: APIs manufacturing plant.
              ChemWerth works in generic API development & supply, non-infringement patent strategy development and regulatory support.
              Post Enquiry
              POST ENQUIRY